Key Highlights
- NPCE shares fell 30.12% pre-market today to $8.40 from a prior close of $12.02.
- Full-year Revenue guidance was cut to $91 million to $92 million.
- Third quarter revenue was $23.1 million, down 1.1% from a year earlier.
- RNS System revenue grew 1.4% to $22.9 million in the quarter.
NeuroPace (NASDAQ:NPCE) shares dropped sharply in pre-market today after the company lowered its full-year revenue guidance alongside third quarter results. The stock was at $8.40, down 30.12% from the prior close of $12.02, which followed a 3.99% decline in the previous session.
Management said third quarter revenue was below its expectations. It pointed to several of its largest accounts, citing isolated account-level issues and field organization changes that caused more disruption than anticipated, and said scheduled fourth quarter cases have begun to recover.
NeuroPace is a Mountain View, California-based medical device company focused on epilepsy. Its RNS System is a brain-responsive neurostimulator that monitors brain activity and delivers stimulation at the seizure source in adults with drug-resistant focal epilepsy.
Revenue Outlook Reset: Lower Sales, Lower Spending, Higher Margin
The company cut 2026 total revenue guidance to between $91 million and $92 million from $99.5 million to $101.5 million, about 9% lower at the midpoint. It said the new range still reflects underlying RNS revenue growth of 10% to 11%.
Non-GAAP Operating Expense guidance fell to $85 million to $86 million from $90 million to $92 million, and non-GAAP gross Margin guidance rose to 83.0% to 83.5% from 82.0% to 83.0%. The Adjusted EBITDA loss forecast widened to $8.5 million to $9.5 million from $7.5 million to $8.5 million.
Flat Third Quarter Sales Meet a Wider Margin and a Narrower Loss
Total revenue slipped 1.1% to $23.1 million from $23.4 million, while RNS System revenue rose 1.4% to $22.9 million. Non-GAAP gross margin improved to 84.8% from 82.8%, and non-GAAP operating expenses fell to $19.2 million from $20.7 million.
The GAAP net loss from continuing operations narrowed to $3.3 million, or $0.10 per share, from $4.9 million. Adjusted EBITDA was positive $0.4 million, compared with a loss of $1.3 million a year earlier.
Cash, cash equivalents, short-term investments and restricted cash were $49.5 million as of September 30, compared with $51.9 million at the end of the prior quarter. Long-term borrowings totaled $59.2 million. The pre-market price sits below the 52-week low of $11.90.
Remote Care Review and IGE Amendment Keep the Regulatory Pipeline Moving
NeuroPace submitted a premarket approval supplement for Remote Care, which would let physicians program the RNS System through telehealth, with a planned 180-day review. After an October meeting with the FDA, it expects to submit an amendment to its idiopathic generalized epilepsy supplement around year end.
It has also begun enrolling AURORA, a real-world evidence study intended to support expanding the indication to adolescents aged 12 to 17 with drug-resistant focal epilepsy, with data collection expected to finish in early 2027.
Fourth-Quarter Case Recovery Is the Test for the Lowered Outlook
The guidance cut centers on revenue, while margin and Adjusted EBITDA improved in the quarter. Management said it is working to return to historical growth rates, and the next Quarterly Report will show whether the fourth quarter case recovery supports the new $91 million to $92 million range.






Please wait processing your request...